Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
2026. dec. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
2026. nov. 10.· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Preprint
Fractional tumor burden refines prognostic stratification beyond MGMT status in glioblastoma after chemoradiotherapy.
2026. okt. 29.· medRxiv : the preprint server for health sciences· PUBMED
Publikáció
MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions.
2026. okt. 13.· Journal of neuro-oncology· PUBMED
Publikáció
EpiDirect enables rapid bisulfite-free MGMT promoter methylation testing in IDH-wildtype glioblastoma with high agreement across established assays.
2026. okt. 5.· Neuro-oncology advances· PUBMED
Vizsgálat
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
2026. okt. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
The Role of Noncoding RNA in MGMT-Positive Glioblastoma: A Narrative Review.
2026. okt. 1.· Cancer medicine· PUBMED
Publikáció
Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine.
2026. szept. 24.· Journal of neuro-oncology· PUBMED
Publikáció
Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
2026. szept. 1.· Nature cancer· PUBMED
Publikáció
Survival Impact of Supramarginal Resection According to MGMT Promoter Methylation Status in Glioblastoma: A Systematic Review and Meta-analysis.
2026. szept. 1.· JPMA. The Journal of the Pakistan Medical Association· PUBMED
Publikáció
Externally validated explainable 3D CNN ensemble model for non-invasive prediction of IDH and MGMT status in gliomas.
2026. aug. 26.· Frontiers in oncology· PUBMED
Publikáció
20(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation.
2026. aug. 17.· Frontiers in medicine· PUBMED
Vizsgálat
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
2026. aug. 10.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Glioblastoma MRI Dataset with Standardized Preprocessing, Expert-Validated Segmentation, and MGMT Profiling.
2026. aug. 7.· Scientific data· PUBMED
Vizsgálat
Temozolomide in Aggressive Pituitary Neuroendocrine Tumors: A Latin American Multicenter Retrospective Cohort (TMZ-LATAM)
2026. aug. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
DNA methylation of silencer-annotated regions at the MGMT locus in the context of promoter and enhancer methylation in glioblastoma and melanoma brain metastases.
2026. aug. 1.· Clinical epigenetics· PUBMED
Publikáció
Low-dose temozolomide combined with valproic acid in the treatment of an elderly patient with MGMT-methylated glioblastoma and multiple comorbidities: a case report.
2026. júl. 30.· Frontiers in oncology· PUBMED
Publikáció
DLK1-35 Contributes to Temozolomide Resistance in Glioblastoma Through the miR-140-3p/NHE1/ERK-MGMT Axis.
2026. júl. 23.· The Tohoku journal of experimental medicine· PUBMED
Publikáció
Extent of resection and survival in IDH-wildtype glioblastoma: interaction with MGMT status and chemoradiation.
2026. júl. 23.· Journal of neuro-oncology· PUBMED
Publikáció
5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex.
2026. júl. 23.· Expert opinion on therapeutic targets· PUBMED
Publikáció
Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.
2026. júl. 23.· Frontiers in oncology· PUBMED
Publikáció
O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report.
2026. júl. 21.· Cureus· PUBMED
Vizsgálat
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
2026. júl. 16.· PHASE3 · RECRUITING· CTGOV
Publikáció
Integrating chemotherapy, radiotherapy, and O6-methylguanine-DNA methyltransferase (MGMT) status with deep-learning cellular tumor volumetry sharpens prediction of glioblastoma recurrence on postoperative MRI.
2026. júl. 9.· Neuro-oncology advances· PUBMED
Publikáció
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma.
2026. júl. 8.· Science translational medicine· PUBMED
Vizsgálat
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
2026. júl. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
E3 ligase LMO7 promotes ALKBH2 ubiquitination to sensitize MGMT-deficient glioblastoma to temozolomide.
2026. jún. 30.· Cell death & disease· PUBMED
Publikáció
Single Institution Retrospective Study to Determine Time to First True Progression in MGMT-Methylated Glioblastoma Patients Who Received Standard of Care.
2026. jún. 29.· Journal of clinical medicine· PUBMED
Publikáció
Impact of weak MGMT promoter methylation on the prognosis of patients with newly diagnosed glioblastoma.
2026. jún. 23.· Journal of neurosurgical sciences· PUBMED
Publikáció
Independent associations of MGMT promoter methylation and TERT promoter mutation with overall survival in glioblastoma: a single-center retrospective cohort study.
2026. jún. 22.· Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology· PUBMED